

SUPPLEMENTARY TABLE 1. Estimated vaccination coverage by age 24 months* among children born 2016-2017,[†] by selected vaccines and doses and race/ethnicity,[§] National Immunization Survey-Child, United States, 2017-2019

Vaccine/Dose	Race/Ethnicity						
	White, non-Hispanic (referent)	Black, non-Hispanic	Hispanic	American Indian/Alaska Native, non-Hispanic	Asian, non-Hispanic	Native Hawaiian or other Pacific Islander, non-Hispanic	Multiple Race, non-Hispanic
	(n = 15,255)	(n = 1,838)	(n = 5,540)	(n = 292)	(n = 1,014)	(n = 96)	(n = 1,935)
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
DTaP[¶]							
≥3 doses	94.2 (93.2-95.1)	92.7 (90.7-94.4)	92.6 (91.1-93.9)	84.9 (74.4-92.7)	94.9 (92.7-96.6)	85.8 (76.8-92.7)**	91.1 (86.2-94.7)
≥4 doses	82.7 (81.3-84.1)	77.0 (73.7-80.2)**	78.1 (75.1-80.9)**	...	84.5 (79.1-89.1)	77.9 (67.2-87.0)	80.3 (75.5-84.7)
Poliovirus (≥3 doses)	93.1 (92.1-94.0)	91.4 (88.7-93.6)	91.4 (89.8-92.9)	84.7 (74.1-92.6)	94.2 (91.4-96.3)	85.8 (76.8-92.7)	89.9 (85.1-93.6)
MMR (≥1 dose)^{††}	91.0 (89.8-92.1)	90.5 (88.2-92.6)	90.2 (88.1-92.1)	88.3 (80.0-94.2)	93.1 (90.5-95.2)	82.3 (72.4-90.3)	89.4 (84.6-93.3)
Hib^{§§}							
Primary series	92.9 (91.6-94.0)	92.8 (90.9-94.5)	91.3 (89.5-92.9)	82.4 (71.5-90.9)**	94.6 (92.4-96.3)	85.6 (76.5-92.5)	90.1 (85.3-93.8)
Full series	81.5 (79.9-83.0)	76.7 (73.3-79.9)**	77.8 (74.8-80.6)**	...	84.6 (79.8-88.8)	...	79.8 (75.1-84.2)
HepB							
Birth dose ^{¶¶}	74.6 (73.1-76.2)	77.0 (73.2-80.4)	78.6 (75.7-81.2)**	...	79.2 (73.3-84.1)	...	77.6 (72.4-82.2)
≥3 doses	91.9 (90.8-92.8)	91.3 (88.7-93.5)	90.8 (88.8-92.5)	86.4 (76.5-93.6)	93.6 (91.2-95.5)	87.1 (78.4-93.5)	89.9 (85.1-93.7)
VAR (≥1 dose)^{††}	89.9 (88.7-91.1)	90.3 (88.0-92.3)	90.1 (87.9-92.0)	87.0 (78.1-93.5)	92.9 (90.4-94.9)**	83.5 (73.7-91.2)	88.8 (84.0-92.7)
PCV							
≥3 doses	92.4 (91.2-93.5)	91.7 (89.7-93.5)	90.7 (89.0-92.3)	83.2 (72.3-91.6)	93.5 (91.1-95.4)	85.5 (76.4-92.5)	90.1 (85.3-93.8)
≥4 doses	84.1 (82.7-85.5)	77.2 (73.7-80.5)**	79.9 (77.0-82.6)**	...	85.4 (81.0-89.3)	...	79.0 (74.2-83.5)**
HepA							
≥1 dose	85.9 (84.5-87.2)	84.6 (81.5-87.4)	86.4 (84.0-88.6)	82.3 (71.8-90.7)	89.9 (86.6-92.7)**	82.1 (72.1-90.1)	83.0 (77.8-87.7)
≥2 doses (by 35 months)	77.1 (75.2-78.9)	75.9 (70.5-81.1)	78.2 (74.3-81.8)	...	82.1 (73.5-89.2)	...	71.6 (64.4-78.4)
Rotavirus (by 8 months)^{***}	79.3 (77.9-80.6)	65.7 (62.0-69.2)**	73.3 (70.2-76.1)**	...	80.0 (75.0-84.1)	...	75.1 (70.1-79.6)
Influenza ≥2 doses^{†††}	62.4 (60.7-64.1)	44.0 (40.3-48.0)**	56.1 (52.8-59.4)**	...	72.8 (67.2-78.2)**	...	53.3 (48.0-58.8)**
Combined 7-vaccine series^{§§§}	72.7 (71.1-74.4)	65.8 (61.9-69.6)**	67.8 (64.5-71.1)**	...	75.1 (69.4-80.5)	...	71.3 (66.4-76.1)
No vaccinations	1.2 (1.0-1.5)	0.9 (0.6-1.4)	1.1 (0.7-1.6)	1.2 (0.7-2.0)

Abbreviations: CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.

* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

[†] Data for the 2016 birth year are from survey years 2017, 2018, and 2019; data for the 2017 birth year are considered preliminary and come from survey years 2018 and 2019 (data from survey year 2020 are not yet available).

§ Children's race/ethnicity was reported by the parent or guardian. Children identified in this report as white, black, Asian, American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, or multiple races were reported by the parent or guardian as non-Hispanic. Children identified as being of multiple races had more than one race category selected. Children identified as Hispanic might be of any race.

¶ Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

** Statistically significant ($p < 0.05$) difference compared with the referent group.

†† Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

§§ Hib primary series: receipt of ≥ 2 or ≥ 3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥ 3 or ≥ 4 doses, depending on product type received.

¶¶ One dose HepB administered from birth through age 3 days.

*** Includes ≥ 2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥ 3 doses of RotaTaq pentavalent rotavirus vaccine (RV5). (If any dose in the series is either RotaTaq or unknown, default to 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.

††† Doses must be at least 24 days apart (four weeks with a four-day grace period); doses could have been received during two influenza seasons.

§§§ The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥ 4 doses of DTaP, ≥ 3 doses of poliovirus vaccine, ≥ 1 dose of measles-containing vaccine, the full series of Hib (≥ 3 or ≥ 4 doses, depending on product type), ≥ 3 doses of HepB, ≥ 1 dose of VAR, and ≥ 4 doses of PCV.

¶¶¶ Estimate not available because the unweighted sample size for the denominator was < 30 , or 95% CI half width/estimate > 0.588 , or 95% CI half-width was ≥ 10 .